In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

Having made waves the world over, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured ... drugs like Ozempic after using them for weight loss. In India, too, the weight loss ...

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 ...

Losing excess weight would in turn improve health. For example, lower levels of sleep apnoea – when breathing stops and ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe ... vice-president Martin Holst Lange said: “Results from STEP UP further strengthen the ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug. The maker of Ozempic and Wegovy said ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...